Jove
Visualize
Contact Us
  1. Home
  3. Clinical Outcomes Following Institution Of The Canadian Universal Leukoreduction Program For Red Blood Cell Transfusions.
  1. Home
  3. Clinical Outcomes Following Institution Of The Canadian Universal Leukoreduction Program For Red Blood Cell Transfusions.

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell

Paul C Hébert1, Dean Fergusson, Morris A Blajchman

  • 1University of Ottawa Centre for Transfusion Research, and Clinical Epidemiology Program of the Ottawa Health Research Institute, Ottawa, Ontario, Canada. phebert@ohri.ca

JAMA
|April 17, 2003

View abstract on PubMed

Summary
This summary is machine-generated.

Universal leukoreduction of blood transfusions may decrease mortality and fever episodes in high-risk patients. This national program showed reduced in-hospital deaths and antibiotic use, suggesting improved patient outcomes.

Related Experiment Videos

Area of Science:

  • Transfusion Medicine
  • Public Health Policy
  • Patient Safety

Background:

  • Universal leukoreduction policies for blood supply are implemented globally.
  • The impact of leukoreduction on postoperative mortality and infection rates remains unclear.

Purpose of the Study:

  • To assess clinical outcomes after implementing a national universal prestorage leukoreduction program for blood transfusions.
  • Evaluate the effect of leukoreduction on mortality, infection, fever, and antibiotic use.

Main Methods:

  • Retrospective before-and-after cohort study (August 1998-August 2000) in 23 Canadian hospitals.
  • 14,786 patients receiving red blood cell transfusions (cardiac surgery, hip fracture repair, intensive care).
  • Compared outcomes before and after the introduction of universal prestorage leukoreduction.

Main Results:

  • Unadjusted mortality rates decreased post-leukoreduction (6.19% vs 7.03%, P=.04).
  • Adjusted odds of death were reduced (OR, 0.87; 95% CI, 0.75-0.99).
  • Serious nosocomial infections did not significantly decrease, but posttransfusion fevers and antibiotic use were reduced.

Conclusions:

  • A national universal leukoreduction program may be associated with decreased mortality in high-risk patients.
  • The program also showed reductions in fever episodes and antibiotic use post-red blood cell transfusion.
  • Further research may clarify the full clinical benefits of universal leukoreduction.